European CHMP recommends approval of selumetinib (Koselugo) for treatment of paediatric neurofibromatosis type 1 plexiform neurofibromas

Selumetinib, an oral selective MEK inhibitor, has been reported to reduce the volume of plexiform neurofibromas and thereby improve clinical outcomes such as pain intensity, mobility and/or disfigurement in patients.

Source:

European Medicines Agency